Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Non-Current Deffered Revenue (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Non-Current Deffered Revenue data on record, last reported at $30.4 million in Q2 2025.

  • For Q2 2025, Non-Current Deffered Revenue fell 44.09% year-over-year to $30.4 million; the TTM value through Jun 2025 reached $30.4 million, down 44.09%, while the annual FY2024 figure was $44.8 million, 32.87% down from the prior year.
  • Non-Current Deffered Revenue reached $30.4 million in Q2 2025 per TNGX's latest filing, down from $37.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $116.6 million in Q3 2021 and bottomed at $5.8 million in Q1 2021.
  • Average Non-Current Deffered Revenue over 5 years is $68.3 million, with a median of $68.7 million recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: soared 1898.7% in 2021, then tumbled 44.09% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $114.7 million in 2021, then fell by 19.73% to $92.1 million in 2022, then decreased by 27.59% to $66.7 million in 2023, then tumbled by 32.87% to $44.8 million in 2024, then crashed by 32.01% to $30.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $30.4 million in Q2 2025, $37.5 million in Q1 2025, and $44.8 million in Q4 2024.